Vyome Seals Strategic Pact With Impetis Biosciences, Unlocking a ~$57 Billion Market Horizon

Vyome Partners With Impetis, a TATA Enterprise, to In‑License Next‑Generation JAK Inhibitors, Unlocking a ~$57B Global Market Opportunity

Vyome has signed a landmark agreement with Impetis Biosciences, a TATA Enterprise, to in‑license two highly selective JAK inhibitor assets, opening access to a large and expanding ~$57 billion global market. These next‑generation inhibitors are engineered for superior selectivity, with the potential to enhance safety compared to earlier pan‑JAK approaches. The transaction underscores Vyome’s ability to source differentiated innovation across the US–India corridor and translate it into strategic value. Structured in a capital‑efficient, commercialization‑linked manner, the deal ensures future development through non‑dilutive pathways, while preserving Vyome’s sharp focus on advancing VT‑1953 execution.

Vyome Holdings, Inc. (Nasdaq: HIND) today announced the signing of a strategic agreement with Impetis Biosciences Limited, a TATA Enterprise, granting Vyome exclusive rights to develop and commercialize two next‑generation selective JAK inhibitor assets: a JAK1/3 inhibitor and a JAK1 inhibitor.

Janus kinase (JAK) inhibitors are a class of immunomodulatory drugs that block JAK enzymes to treat autoimmune and inflammatory conditions. Several JAK inhibitors are already FDA‑approved for diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, alopecia areata, and atopic dermatitis. However, earlier pan‑JAK approaches have been associated with safety risks, prompting FDA warnings. The selective inhibitors licensed by Vyome are designed to overcome these limitations, offering higher precision and improved safety profiles.

The global JAK inhibitor market, valued at $23.56 billion in 2025, is projected to reach $56.78 billion by 2030, growing at a CAGR of 19.5%. This transaction positions Vyome to capture a significant share of this ~$57 billion opportunity while reinforcing its ability to source differentiated innovation across the US–India corridor.

“We are delighted that Impetis trusted the Vyome team to lead the development of such valuable assets. Selective JAK inhibitors represent the future of immunology, and Impetis has provided compelling preclinical data showing clear differentiation from earlier generations,” said Dr. Shiladitya Sengupta, Co‑Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “While we remain focused on advancing our lead asset VT‑1953 for malignant fungating wounds, these JAK inhibitors expand our portfolio into new and large immune‑inflammatory therapeutic areas.”

Vyome CEO Venkat Nelabhotla added: “We are building Vyome with focus and discipline in one of the most attractive biotech segments—the immuno‑inflammatory market, expected to exceed $430 billion by 2034. This transaction highlights the strength of the US–India innovation corridor and is structured to be capital‑efficient, with consideration tied to commercialization. Future development will be pursued through non‑dilutive pathways, allowing us to remain fully focused on executing our VT‑1953 strategy.”

Mr. KRS Jamwal, Chairman of Impetis, remarked: “We are pleased to partner with Vyome on the development of our JAK inhibitor programs. This collaboration reflects Impetis’ commitment to translating its deep preclinical portfolio into clinical value.”

---

About Vyome Holdings, Inc.

Based in Cambridge, MA, Vyome is focused on leveraging its clinical‑stage assets to transform the lives of patients with immuno‑inflammatory conditions. By applying groundbreaking science and its unique positioning across the US–India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a cost‑efficient manner while upholding global standards of quality and safety. 

About Impetis Biosciences Limited

Headquartered in Mumbai, India, Impetis Biosciences Limited advances a portfolio of differentiated preclinical‑stage drug candidates across immuno‑inflammatory, immuno‑oncology, and metabolic disease areas. Its pipeline includes BTK inhibitors, a liver‑selective glucokinase activator for Type 2 diabetes, and novel programs targeting RORγt and GPR91. Impetis progresses its assets through global licensing partnerships designed to translate pharmaceutical innovation into clinical value for patients with significant unmet needs.